



Frontline Treatment of DLBCL: Practice Implications

References

1. Campo E, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood*. Sep 15 2022;140:1229-1253. doi:10.1182/blood.2022015851
2. Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. May 19 2016;127:2375-90. doi:10.1182/blood-2016-01-643569
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): B-Cell Lymphomas. Updated February 8, 2023. Accessed March 27, 2023, https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
4. Feugier P, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. Jun 20 2005;23:4117-26. doi:10.1200/jco.2005.09.131
5. Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood*. Sep 23 2010;116:2040-5. doi:10.1182/blood-2010-03-276246
6. Récher C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. *Lancet*. Nov 26 2011;378:1858-67. doi:10.1016/s0140-6736(11)61040-4
7. Cunningham D, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet*. May 25 2013;381:1817-26. doi:10.1016/s0140-6736(13)60313-x
8. Delarue R, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. *Lancet Oncol*. May 2013;14:525-33. doi:10.1016/s1470-2045(13)70122-0
9. Vitolo U, et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. Nov 1 2017;35:3529-3537. doi:10.1200/jco.2017.73.3402
10. Bartlett NL, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. *J Clin Oncol*. Jul 20 2019;37:1790-1799. doi:10.1200/jco.18.01994
11. Rozental A, et al. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis. *Hematol Oncol*. 2019;37:27-34. doi:<https://doi.org/10.1002/hon.2561>
12. Davies A, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. *Lancet Oncol*. May 2019;20:649-662. doi:10.1016/s1470-2045(18)30935-5
13. Younes A, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. May 20 2019;37:1285-1295. doi:10.1200/jco.18.02403
14. Castellino A, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. *Blood Cancer J*. Nov 8 2018;8:108. doi:10.1038/s41408-018-0145-9



15. Morschhauser F, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. *Blood*. Feb 4 2021;137:600-609. doi:10.1182/blood.2020006578
16. Zelenetz AD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. *Blood*. May 2 2019;133:1964-1976. doi:10.1182/blood-2018-11-880526
17. Sehn LH, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. Jan 10 2020;38:155-165. doi:10.1200/jco.19.00172
18. Tilly H, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med*. Jan 27 2022;386:351-363. doi:10.1056/NEJMoa2115304
19. Wilson WH, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nat Med*. Aug 2015;21:922-6. doi:10.1038/nm.3884
20. Wilson WH, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. *Cancer Cell*. Dec 13 2021;39:1643-1653.e3. doi:10.1016/j.ccell.2021.10.006
21. Schmitz R, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N Engl J Med*. Apr 12 2018;378:1396-1407. doi:10.1056/NEJMoa1801445

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Bristol Myers Squibb and Genentech, a member of the Roche Group.